Over the past few decades, immune checkpoint inhibitors (ICIs), which are antibodies that target inhibitory immune checkpoint molecules such as programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4), have revolutionized cancer treatment. Here, CD274 is linked to cancer.